Immune scores in colorectal cancer: Where are we?

[1]  W. Scheithauer,et al.  Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. , 2020, European journal of cancer.

[2]  P. Laurent-Puig,et al.  Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  N. Wolmark,et al.  Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. , 2019 .

[4]  Wenxue Liu,et al.  The main contributor to the upswing of survival in locally advanced colorectal cancer: an analysis of the SEER database , 2019, Therapeutic advances in gastroenterology.

[5]  M. Bertagnolli,et al.  Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Donna Niedzwiecki,et al.  Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Taieb,et al.  Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. , 2019, Cancer treatment reviews.

[8]  A. Debucquoy,et al.  The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. , 2018, Cancer cell.

[9]  Michael Barnes,et al.  Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis , 2018, Clinical Cancer Research.

[10]  F. Marincola,et al.  Evolution of Metastases in Space and Time under Immune Selection , 2018, Cell.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[13]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Sargent,et al.  Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials , 2017, JAMA oncology.

[15]  J. Machiels,et al.  Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival , 2018, Journal of the National Cancer Institute.

[16]  P. Laurent-Puig,et al.  The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors , 2018, Journal of the National Cancer Institute.

[17]  Yun Wang,et al.  The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases , 2018, Cancer Immunology, Immunotherapy.

[18]  P. Laurent-Puig,et al.  Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. , 2017, European journal of cancer.

[19]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[20]  D. McMillan,et al.  Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer , 2017, British Journal of Cancer.

[21]  M. Salto‐Tellez,et al.  Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population‐based study , 2017, Histopathology.

[22]  H. Lee,et al.  Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer , 2016, Oncotarget.

[23]  Stephen B Gruber,et al.  Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer. , 2016, Journal of the National Cancer Institute.

[24]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[25]  D. Aust,et al.  Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. , 2015, European journal of cancer.

[26]  J. Galon,et al.  Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. , 2015, Cancer research.

[27]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[28]  L. Qin,et al.  Genetic Evidence That Intratumoral T-cell Proliferation and Activation Are Associated with Recurrence and Survival in Patients with Resected Colorectal Liver Metastases , 2015, Cancer Immunology Research.

[29]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[30]  H. Schlitt,et al.  Prognosis according to histochemical analysis of liver metastases removed at liver resection , 2014, The British journal of surgery.

[31]  E. Tartour,et al.  Colorectal cancer and immunity: what we know and perspectives. , 2014, World journal of gastroenterology.

[32]  J. Galon,et al.  Imaging , Diagnosis , Prognosis Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer , 2014 .

[33]  I. Endo,et al.  Low Infiltration of Peritumoral Regulatory T Cells Predicts Worse Outcome Following Resection of Colorectal Liver Metastases , 2014, Annals of Surgical Oncology.

[34]  R. Palmqvist,et al.  Phenotypic Skewing of Macrophages In Vitro by Secreted Factors from Colorectal Cancer Cells , 2013, PloS one.

[35]  M. Gonen,et al.  Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases , 2013, Annals of Surgical Oncology.

[36]  B. Nordlinger,et al.  Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor , 2012, Diagnostic Pathology.

[37]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[38]  E. Aandahl,et al.  Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer , 2012, Cancer Immunology, Immunotherapy.

[39]  A. Israni,et al.  Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.

[40]  Axel Benner,et al.  Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. , 2011, Cancer research.

[41]  Zlatko Trajanoski,et al.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Shuji Ogino,et al.  Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.

[43]  J. Neuberger,et al.  Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[44]  Zlatko Trajanoski,et al.  Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. , 2010, Gastroenterology.

[45]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Mari Mino-Kenudson,et al.  Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype , 2009, Clinical Cancer Research.

[47]  M. Gonen,et al.  T Cell Infiltrate Predicts Long-Term Survival Following Resection of Colorectal Cancer Liver Metastases , 2009, Annals of Surgical Oncology.

[48]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[49]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[50]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[51]  A. Mori,et al.  Increased Intratumor Vα24-Positive Natural Killer T Cells: A Prognostic Factor for Primary Colorectal Carcinomas , 2005, Clinical Cancer Research.

[52]  M. Bonneville,et al.  Vγ9Vδ2 T Cell Response to Colon Carcinoma Cells1 , 2005, The Journal of Immunology.

[53]  C. Ostwald,et al.  Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. , 2004, Human pathology.

[54]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[55]  M. A. Sáez,et al.  The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.